EUROPEAN ACADEMIC RESEARCH institutions and pharmaceutical companies have teamed up to encourage the development of treatments for rare diseases. The goal of the European Rare Diseases Therapeutic Initiative (ERDITI): to promote the evaluation of compounds that have been abandoned by drug companies.Although development of drugs for rare diseases benefits from orphan drug legislation in Europe and the United States, most companies cannot justify the cost of traditional pharmaceutical research, including screening of compounds and preclinical development.
展开▼
